Yes – in that
way: we have so many failures of a targeted approach that I plan to count it. I
have already written about 10 failures (probably 20) since I started the blog,
so this article will be No 11.
Ok, this
time the failure concerning Ampyra:
a potassium channel
blocker approved in the US in 2010 as a treatment for improving walking in
patients with MS.
However, the medicine can cause seizures,
and as this risk increases the higher the dose, US regulators asked Acorda to
investigate whether a 5mg twice daily version is as effective as the approved
10mg twice a day.
The four-week study randomised 430
participants to receive either placebo, or 5mg or 10mg of Ampyra twice daily.
Unfortunately, neither dose of the Acorda's
drug showed a stastically-significant improvement in the primary endpoint -
change in walking speed - compared with the placebo arm.
Well,
simple structure – simple failure.
No comments:
Post a Comment